Alpha-fetoprotein (AFP)

Overview

Alpha-fetoprotein (AFP) is a glycoprotein and well-established serum tumor marker, best known for its clinical association with hepatocellular carcinoma (HCC). It is also used in the evaluation of other AFP-producing malignancies, including alpha-fetoprotein-producing gastric cancer, where elevated serum AFP can correlate with tumor stage and prognosis. In routine practice, AFP is primarily valued as a biomarker for detection, risk stratification, and disease monitoring rather than as a standalone diagnostic test.

Beyond its biomarker role, recent research has increasingly examined AFP as a biologically active molecule in cancer. In hepatocellular carcinoma, AFP has been investigated as a regulator of cancer stemness and tumor progression, including signaling through the PI3K/Akt signaling pathway. This broader functional perspective has prompted studies of AFP in relation to tumor biology, glycoprotein recognition, and assay development, alongside related cancer markers such as Carcinoembryonic antigen (CEA), Epithelial Cell Adhesion Molecule (EpCAM), CD44, Human epidermal growth factor receptor 2 (HER2), and TP53.

Recent Publications Summary

Alpha-fetoprotein remains the anchor analyte for hepatocellular carcinoma detection, and much of the recent work using AFP as a target is analytical rather than therapeutic, treating the glycoprotein as a benchmark for new biosensing chemistries. An entropy-driven autocatalysis scheme was coupled to a signal-on CRISPR/Cas12a assay on a DNA triangular prism scaffold, in which amplification output strands act as Cas12a inhibitors so that signal generation is strictly coupled to target presence, avoiding the high background of conventional signal-off designs 42335458Jun. A polymeric membrane ion-selective electrode operated under pulsed galvanostatic chronopotentiometry rather than zero-current potentiometry used heparin polysaccharide as a multi-charge, large-volume indicator ion, achieving detection limits of 1.92 pg/mL for a concanavalin A-based electrode and 4.10 fg/mL for an antibody-based electrode, with good recoveries in spiked mouse and human serum; the concanavalin A format also probed glycan–lectin recognition of the AFP glycan chain 42174235May. A neocuproine-boosted copper metal-organic framework nanozyme enhanced multi-hydrolase-mimicking activity 2.8- to 23.6-fold and generated a colored Cu(I)–neocuproine chelate, supporting a five-minute colorimetric immunosensor with a 5–100 ng/mL range and a 1.4 ng/mL limit of detection in real serum 41764904Mar.

Several platforms push AFP measurement toward point-of-care use. A microfluidic photonic crystal chip combined fluorescence enhancement from photonic crystal arrays with on-chip membrane filtration to replace centrifugation, quantifying AFP from a single droplet of blood with a 0.1 ng/mL detection limit and a 1–1600 ng/mL linear range; double-blinded comparison against ELISA across 70 clinical samples gave a Pearson correlation of R² = 0.981 and a mean bias of −5.15 ng/mL 42132692May. A hierarchically mesoporous, channel-confined nanozyme reactor built from polydopamine scaffolds and platinum nanozymes within magnetic dendritic mesoporous silica amplified gold plasmonic signal 125-fold over conventional gold nanoparticles and 5-fold over nonporous nanozymes of similar size, enabling dual qualitative/quantitative lateral flow readout of AFP alongside cardiac troponin I as a multiplex biomarker panel 42063290May. AFP has also been repurposed as a recognition element rather than a soluble analyte: a dual-mode SERS/electrochemical sensor on a single gold nanowire paired CD63 aptamer-functionalized DNA tetrahedrons for exosome capture with AFP-mediated signal tagging, using the two-step recognition to improve specificity toward HepG2-derived exosomes in a liver cancer liquid biopsy format 42190059May.

On the clinical side, log-transformed serum AFP and des-γ-carboxy prothrombin were evaluated for their impact on early HCC recurrence after hepatectomy and incorporated into a nomogram for postoperative risk stratification 42379778Jun. Interpretation of AFP in pediatric practice was addressed in a prospective cross-sectional study of 3,680 healthy Vietnamese children from birth to under 19 years measured on the Roche Cobas Pro platform: concentrations peaked in the neonatal period and fell steeply over the first months of life before stabilizing, sex differences were minimal and did not justify sex-specific intervals, and GAMLSS-based continuous age-specific reference intervals for ages 0 to under 3 years were proposed to handle the rapid early decline that discrete intervals obscure 41996693Apr.

Beyond the liver, AFP-producing gastric cancer is described as a distinct entity, mostly falling in the chromosomal instability subtype with TP53 and MUC16 mutations and amplification of ERBB2 and CCNE1. Serum AFP is typically markedly elevated and correlates with T-stage and prognosis, though discordant cases show intra-tumoral AFP positivity with normal serum levels; intra-tumoral AFP is implicated in invasiveness and immune evasion, potentially promoting proliferation and metastasis by modulating immune cell activity and remodeling the tumor milieu toward an immunosuppressive phenotype, and co-elevation of AFP with other markers has been examined clinically.

The one therapeutic application targets AFP as a tumor antigen. A bivalent mRNA neoantigen vaccine delivered epitopes of AFP and Glypican-3 in spleen-homing CL15H6 lipid nanoparticle to splenic dendritic cells by intravenous administration; the formulation outperformed clinically relevant comparators in mRNA delivery, antigen presentation, and co-stimulatory molecule expression, elicited a higher proportion of antigen-specific cytotoxic T lymphocytes, and two prophylactic doses completely protected mice from hepatocellular carcinoma challenge, with biosafety assessed by histopathology, serology, and cytokine profiling 42442546Jul.

What Changes, What Holds

1. AFP is increasingly a benchmark analyte for assay engineering rather than only a clinical marker
METHOD These studies do not alter AFP’s established role in hepatocellular carcinoma or other AFP-producing Cancers; they show that recent work is using AFP to stress-test and compare sensing chemistries, signal amplification schemes, and glycan-recognition formats 42335458Jun42174235May. The practical implication is methodological: AFP is serving as a standard target for pushing detection limits and background suppression, not as evidence for a new biological function.

2. Point-of-care AFP testing is becoming more plausible, but the clinical role remains the same
METHOD The new platforms mainly change how AFP can be measured, not what AFP means clinically: they move detection toward droplet-scale, rapid, and multiplex formats while preserving the biomarker use already described in the Overview 42132692May42063290May. The exosome sensor is especially a measurement innovation, because AFP is being used in signal tagging within a liquid-biopsy workflow rather than as a soluble disease marker, which broadens assay design without displacing the baseline account.

3. AFP-based risk stratification is being refined, and pediatric interpretation needs age-specific reference ranges
REINFORCES These findings sharpen the established biomarker role by showing that AFP and related markers can be folded into postoperative recurrence models, while also addressing a major interpretive gap in children 42379778Jun41996693Apr. Nothing here challenges AFP’s clinical use; instead, the work supports more context-sensitive interpretation, especially the need to avoid adult-style or coarse age bins during the rapid neonatal decline.

4. AFP-producing gastric cancer looks biologically more complex than a simple serum marker relationship
NEW DIRECTION The new work extends the Overview’s note that AFP-producing gastric cancer is prognostic by adding a tumor-intrinsic and immune-modulatory dimension that the baseline does not cover. Serum AFP still tracks stage and outcome, but intra-tumoral AFP is now implicated in invasiveness and immune evasion, so AFP may matter not only as a readout of disease burden but also as part of the tumor biology itself.

5. AFP is emerging as a vaccine antigen, not just a marker
NEW DIRECTION This work departs from the Overview’s biomarker-centered account by using AFP as an immunologic target for active therapy, which the baseline does not yet include 42442546Jul. The finding is preclinical and needs confirmation in safety, durability, and human immunogenicity studies, but it suggests AFP can function as a tumor antigen in addition to a serum marker, especially in hepatocellular carcinoma.

Overview update candidates: pediatric age-specific AFP reference intervals; AFP as a tumor antigen for vaccine design; intra-tumoral AFP contributing to gastric cancer invasiveness and immune evasion.